FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.844,54 -1.363,73 (-2,27%)
ARCH THERAPEUTICS INC ARCH THER (0HHJ.L)
| Chiusura precedente | 0,0706 |
| Aperto | 0,0000 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 1 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 3,56 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 20 mag 2024 - 24 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireArch Therapeutics Provides AC5® Commercialization Update
Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi
- GlobeNewswire
Arch Therapeutics Completes Financing as Bridge to Uplisting
Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the
